Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RAB001 in Healthy Subjects

NCT07545018 is registered in ClinicalTrials.gov with ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd. as lead sponsor.

NCT NCT07545018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07545018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RAB001 in Healthy Subjects
Lead sponsor
ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.
Phase
Phase 1
Overall status
Completed
Start date
February 10, 2023
Completion date
July 5, 2023
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteonecrosis of the femoral head